All News

This convinces me! #TNF inhibitors vs #JAKI great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
The #ACR20 Great Debate is on! One issue point is lab monitoring on TNF vs JAK. What's your take? @RheumNow

Eric Dein ejdein1 ( View Tweet)

More UPA safety studies Abst#0215 shows balanced VTE event rates across UPA doses and comparator groups. Evidence for Dr. Strand to use in #ACR20 Great Debate that VTE may be safe TNF alternative @RheumNow. https://t.co/hByttIxiuX
Eric Dein ejdein1 ( View Tweet)
Great debate by Dr. Weinblatt and Dr. Strand on JAKinibs vs TNFi in RA! How long do you tx with JAKinibs before calling it a failure? @RheumNow #ACR20 #ACRbest

Robert B Chao, MD doctorRBC ( View Tweet)

Dr. Weinblatt dodges the question which TNFi prefers after MTX-IR. Which one do you choose? #ACR20 #GreatDebate @RheumNow

k dao KDAO2011 ( View Tweet)

infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

d Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
moneyglobe.jpg

US Differs from Worldwide Drug Reimbursements

d Jack Cush, MD

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Read Article
Korea National Health databased looked at Fracture rates in RA patients taking TNFis, abatacept, or tocilizumab betw 2002 to 2016. They found no difference in Fx risk related to the biologic taken. https://t.co/W2dWWseXTc

Links:

Dr. John Cush RheumNow ( View Tweet)

choices2.jpg

TNF Inhibitors or non-TNF Biologics - First Best Choice?

d Jack Cush, MD

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

d Jack Cush, MD

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
Nonradiographic axial spondyloarthritis= meeting axSpA criteria without Xray sacroiliitis. Swiss study compared women & men w nr-axSpA. Women had a longer Dx delay, higher Dz activity & enthesitis, less B27+ & signif lower TNFi resp rate (OR 0.19) vs Men https://t.co/ykAHfimOd5

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> https://t.co/ced3cKg5eB or listent to podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/e4nWr3wECz

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 193 Axial SpA pts with TNF inhibitor switching shows, using stringent outcome measures (ASDAS-ID) shows odds of responding to 2nd TNFi best w/ secondary TNFi failure (OR 7.3) or adverse events (OR 9.1), compared to primary TNFi failure. https://t.co/kpDelzBYRe

Links:

Dr. John Cush RheumNow ( View Tweet)

Incredible lecture on the highest of therapeutics for rheumatoid arthritis by @BrighamWomens Dr Michael Weinblatt. Love this screen shot of A to Z for therapies prior to the methotrexate era. Z=Zero therapy (do nothing). Incredible advances since then! https://t.co/AOIMBJiulo
Jeff Sparks jeffsparks ( View Tweet)
ASSERT looked at ankylosing spondylitis (AS) pts treated with infliximab (n = 16) or placebo (n = 7). Infliximab was shown to reduce depression & depressive symptoms by improving AS disease Sxs. There was no link between CRP inflammation & depression https://t.co/oC5rQP2Jec

Links:

Dr. John Cush RheumNow ( View Tweet)

guidelines.recommendations.jpg

EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management

d Jack Cush, MD

In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.

Read Article
podcast logo

RheumNow Podcast – Lupus Delights (9.18.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
Retrospective cohort study of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater risk of hospitalized or ventilation and immunosuppressive use was not shown to worsened the course of disease (TNFi decreased risk of hospitalization) https://t.co/gmIXDJkLCt

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.